Seer, Inc. (SEER) Misses Q4 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seer Reports Fourth Quarter and Full Year 2020 Financial Results and Fuels Commercial Progress in 2021 with New Collaborators and Partnerships
March 29, 2021 4:05 PM EDTREDWOOD CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the quarter and full year ended December 31, 2020.
I am extremely proud of the progress we have made to date and the enthusiasm in the market surrounding our Proteograph Product Suite, said Omid Farokhzad, Chair and Chief Executive Officer. Since January, we have brought on two new collaboration customers, signed three commercial agreements, and entered the second phase of our commercialization plan. We, along with our... More
